改善心衰试验中代表性不足种族和族裔人群的入组:心衰合作组织的行动呼吁
该文指出黑人和西班牙裔心衰患者负担重但在心衰临床试验中代表性不足,影响研究结果的普适性。尽管有FDA和NIH政策,入组差距持续存在,试验全球化、医疗可及性不平等、入组标准限制和英语要求是障碍。改善策略包括研究设计与站点选择、研究领导与人员多元化、放宽入选标准、社区与患者参与及多方承诺。
要点
- 黑人和西班牙裔心衰患者临床试验代表性不足,影响结果外推。
- 入组障碍包括医疗可及性不平等、后勤问题、限制性标准和英语要求。
- 改善策略包括多元化研究团队、放宽标准、社区参与和多利益方承诺。
核心结论
- 心衰试验中代表性不足的种族和族裔人群入组改善是可行且高效的,可提高试验知识的普适性和临床转化。
研究设计与样本
- 本文为心衰合作组织(Heart Failure Collaboratory)的行动呼吁,总结观察并提策略,非原始研究。
主要发现
- 尽管有FDA和NIH政策,心衰试验入组与人群种族族裔构成相称的差距持续存在。
- 试验全球化且美国入组有限是这些模式的主要驱动因素。
- 额外障碍包括医疗可及性不平等、参与后勤问题、限制性入组标准和英语语言要求。
临床怎么用
- 采用方法学研究设计和站点选择以改善多样化入组。
- 多元化研究领导和员工,拓宽入选标准,加强社区和患者参与,并争取广泛利益相关方承诺。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Despite bearing a disproportionate burden of heart failure (HF), Black and Hispanic individuals have been poorly represented in HF clinical trials. Underrepresentation in clinical trials limits the generalizability of the findings to these populations and may even introduce uncertainties and hesitancy when translating trial data to the care of people from underrepresented groups. The Heart Failure Collaboratory, a consortium of stakeholders convened to enhance HF therapeutic development, has been dedicated to improving recruitment strategies for patients from diverse and historically underrepresented groups. OBSERVATIONS: Despite federal policies from the US Food and Drug Administration and National Institutes of Health aimed at improving trial representation, gaps in trial enrollment proportionate to the racial and ethnic composition of the HF population have persisted. Increasing trial globalization with limited US enrollment is a major driver of these patterns. Additional barriers to representative enrollment include inequities in care access, logistical issues in participation, restrictive enrollment criteria, and English language requirements. CONCLUSIONS AND RELEVANCE: Strategies for improving diverse trial enrollment include methodical study design and site selection, diversification of research leadership and staff, broadening of eligibility criteria, community and patient engagement, and broad stakeholder commitment. In contemporary HF trials, diverse trial enrollment is not only feasible but can be efficiently achieved to improve the generalizability and translation of trial knowledge to clinical practice.
引用
- DeFilippis, Echols, Adamson, et al. Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials: A Call to Action From the Heart Failure Collaboratory. JAMA Cardiol. 2022. PMID: 35319725. doi:10.1001/jamacardio.2022.0161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。